V VIKING THERAPEUTICS INC
| Market Cap | $3.86B |
| P/E Ratio | — |
| Forward P/E | -7.31 |
| Dividend Yield | — |
| Beta | 0.79 |
| 52W Range | $18.92 - $43.15 |
| # Hedge Funds | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 0 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|
Insider Trading
| Insider Name of the company insider who made the trade 35 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Aubuchon Neil WilliamChief Commercial Officer | Buy | 4,475 | $33.50 | $149.91K | 10 Mar 2026 | 10 Mar 2026 |
| Lian BrianPresident & CEO | Sale | 41,276 | $34.22 | $1.41M | 05 Jan 2026 | 05 Jan 2026 |
| Lian BrianPresident & CEO | Sale | 53,279 | $33.38 | $1.78M | 05 Jan 2026 | 05 Jan 2026 |
| Lian BrianPresident & CEO | Sale | 132,454 | $32.29 | $4.28M | 05 Jan 2026 | 05 Jan 2026 |
| ZANTE GREGChief Financial Officer | Sale | 10,300 | $34.24 | $352.63K | 05 Jan 2026 | 05 Jan 2026 |
| ZANTE GREGChief Financial Officer | Sale | 13,900 | $33.38 | $464.02K | 05 Jan 2026 | 05 Jan 2026 |
| Mancini MariannaChief Operating Officer | Sale | 1,600 | $35.07 | $56.12K | 05 Jan 2026 | 05 Jan 2026 |
| Mancini MariannaChief Operating Officer | Sale | 10,500 | $34.22 | $359.30K | 05 Jan 2026 | 05 Jan 2026 |
| Mancini MariannaChief Operating Officer | Sale | 13,600 | $33.37 | $453.88K | 05 Jan 2026 | 05 Jan 2026 |
| Mancini MariannaChief Operating Officer | Sale | 31,961 | $32.29 | $1.03M | 05 Jan 2026 | 05 Jan 2026 |
| Lian BrianPresident & CEO | Sale | 6,400 | $35.07 | $224.42K | 05 Jan 2026 | 05 Jan 2026 |
| ZANTE GREGChief Financial Officer | Sale | 1,500 | $32.09 | $48.13K | 05 Jan 2026 | 05 Jan 2026 |
| ZANTE GREGChief Financial Officer | Sale | 31,961 | $32.30 | $1.03M | 05 Jan 2026 | 05 Jan 2026 |
| Greg ZanteChief Financial Officer | Sale | 1,500 | $32.09 | $48.13K | 05 Jan 2026 | 05 Jan 2026 |
| Greg ZanteChief Financial Officer | Sale | 10,300 | $34.24 | $352.63K | 05 Jan 2026 | 05 Jan 2026 |
| Greg ZanteChief Financial Officer | Sale | 13,900 | $33.38 | $464.02K | 05 Jan 2026 | 05 Jan 2026 |
| Greg ZanteChief Financial Officer | Sale | 31,961 | $32.30 | $1.03M | 05 Jan 2026 | 05 Jan 2026 |
| Marianna ManciniChief Operating Officer | Sale | 10,500 | $34.22 | $359.30K | 05 Jan 2026 | 05 Jan 2026 |
| Marianna ManciniChief Operating Officer | Sale | 31,961 | $32.29 | $1.03M | 05 Jan 2026 | 05 Jan 2026 |
| Brian LianPresident & CEO | Sale | 132,454 | $32.29 | $4.28M | 05 Jan 2026 | 05 Jan 2026 |
| Marianna ManciniChief Operating Officer | Sale | 1,600 | $35.07 | $56.12K | 05 Jan 2026 | 05 Jan 2026 |
| Marianna ManciniChief Operating Officer | Sale | 13,600 | $33.37 | $453.88K | 05 Jan 2026 | 05 Jan 2026 |
| Brian LianPresident & CEO | Sale | 6,400 | $35.07 | $224.42K | 05 Jan 2026 | 05 Jan 2026 |
| Brian LianPresident & CEO | Sale | 41,276 | $34.22 | $1.41M | 05 Jan 2026 | 05 Jan 2026 |
| Brian LianPresident & CEO | Sale | 53,279 | $33.38 | $1.78M | 05 Jan 2026 | 05 Jan 2026 |
| FOEHR MATTHEW W | Sale | 16,000 | $35.11 | $561.69K | 02 Jan 2026 | 05 Jan 2026 |
| Matthew W FoehrDirector | Sale | 16,000 | $35.11 | $561.69K | 02 Jan 2026 | 05 Jan 2026 |
| ZANTE GREGChief Financial Officer | Sale | 6,185 | $35.00 | $216.48K | 28 Oct 2025 | 28 Oct 2025 |
| Mancini MariannaChief Operating Officer | Sale | 6,185 | $35.00 | $216.49K | 28 Oct 2025 | 28 Oct 2025 |
| Lian BrianPresident & CEO | Sale | 38,989 | $35.01 | $1.36M | 28 Oct 2025 | 28 Oct 2025 |
| Greg ZanteChief Financial Officer | Sale | 6,185 | $35.00 | $216.48K | 28 Oct 2025 | 28 Oct 2025 |
| Brian LianPresident & CEO | Sale | 38,989 | $35.01 | $1.36M | 28 Oct 2025 | 28 Oct 2025 |
| Marianna ManciniChief Operating Officer | Sale | 6,185 | $35.00 | $216.49K | 28 Oct 2025 | 28 Oct 2025 |
| Rowland Charles A Jr | Sale | 60,000 | $35.57 | $2.13M | 27 Oct 2025 | 28 Oct 2025 |
| Charles A Rowland JrDirector | Sale | 60,000 | $35.57 | $2.13M | 27 Oct 2025 | 28 Oct 2025 |
Frequently Asked Questions
What is VKTX stock price today?
VIKING THERAPEUTICS INC (VKTX) is currently trading at $33.44. The stock has a 52-week range of $18.92 to $43.15 and a market capitalization of $3.86B.
Is VKTX a good stock to buy in 2026?
VIKING THERAPEUTICS INC has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +19.3%. 0 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling VKTX stock?
There have been 35 insider transactions for VKTX in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has VKTX stock performed over the past year?
VIKING THERAPEUTICS INC (VKTX) has returned +19.3% over the past 12 months. The stock traded between $18.92 and $43.15 during this period, and is currently at $33.44.
Which hedge funds own VKTX (VIKING THERAPEUTICS INC)?
0 tracked hedge funds currently hold VKTX in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is VKTX's market cap and valuation?
VIKING THERAPEUTICS INC (VKTX) has a market capitalization of $3.86B. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is VKTX's revenue and profitability?
VIKING THERAPEUTICS INC reported revenue of N/A with net income of N/A and a profit margin of N/A. The stock has a beta of 0.79.
What sector is VKTX in and who are its biggest institutional holders?
VIKING THERAPEUTICS INC (VKTX) operates in the Healthcare sector. It is held by 0 tracked hedge funds. See the ownership table above for the complete list.